Everolimus provides new hope for neuroendocrine tumours

In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced, nonfunctional neuroendocrine tumors (NET) of the lung and gastrointestinal tract.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news